Disc Medicine, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 21, 2024. Although the request references 2023 Q4, the filing reports full-year results, not standalone fourth-quarter results.
Business context
Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic diseases involving heme biosynthesis and iron homeostasis. Its lead programs are bitopertin for erythropoietic porphyrias, DISC-0974 for anemia associated with myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera. DISC-0998 remains preclinical. The company has no approved products and has not generated product-sale revenue.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $69.3 million | $33.4 million |
| General and administrative expense | $21.9 million | $14.0 million |
| Total operating expenses / operating loss | $91.1 million | $47.5 million |
| Interest income | $14.8 million | $0.7 million |
| Net loss | $76.4 million | $46.8 million |
| Net loss per share, basic and diluted | $3.42 | $45.05 |
| Net cash used in operating activities | $73.5 million | $42.3 million |
Gross margin is not applicable because the company had no product revenue. Losses widened as development spending increased; higher interest income partially offset operating losses. The unusually large change in loss per share between years should be read in light of the 2022 merger, reverse recapitalization and share-count changes.
Cash and cash equivalents were $360.4 million at year-end 2023, compared with $194.6 million a year earlier. Current assets were $365.7 million and current liabilities were $21.4 million. Total liabilities were $22.9 million, primarily accounts payable, accruals and operating lease liabilities; the filing reports no borrowings or other debt. Undiscounted operating lease commitments totaled $2.4 million. Management said existing cash was expected to fund planned operating and capital requirements well into 2026, while noting that this estimate depends on assumptions and spending is expected to rise.
Financing activities provided $239.4 million in 2023, principally from a follow-on offering, a registered direct offering and at-the-market sales. These equity financings increased the share count and diluted existing holders. Operating cash use rose year over year; the company expects continuing operating losses and negative operating cash flow.
Material changes and notable items
- R&D expense increased $35.8 million, driven mainly by $20.2 million of DISC-3405 costs, including $15.0 million in upfront and milestone license fees; higher bitopertin development and manufacturing activity; and increased R&D personnel costs.
- G&A expense increased $7.8 million, reflecting higher personnel and public-company costs.
- 2023 interim BEACON data showed a greater-than-40% reduction in metal-free PPIX in the overall study population, along with reported improvements in light tolerance and quality of life. The open-label study was small and the results were interim.
- Interim DISC-0974 data in myelofibrosis showed hepcidin and iron changes and hemoglobin increases in some evaluable participants; the CKD study reported initial single-dose findings. These are early, interim results, not confirmatory efficacy evidence.
- The company recognized a $1.5 million CVR liability in 2023 related to a potential sale of former Gemini assets, then reversed it when the disposition period expired without a sale. No CVR payment will be made. The company also reported approximately $1.6 million of 2023 costs to maintain those assets while meeting its CVR obligations.
Outlook, risks and contingencies
Management expected AURORA Phase 2 topline data in March or April 2024, additional BEACON analysis during 2024, further DISC-0974 interim data in 2024, and DISC-3405 interim data during the first and second halves of 2024. These are expectations stated in the filing, not guaranteed milestones.
Key risks include clinical-trial failure or delay, uncertain interpretation of preliminary results, safety findings, enrollment challenges, regulatory uncertainty, and dependence on CROs and single-source contract manufacturers. The company also faces substantial future funding needs; additional capital may be unavailable or may dilute shareholders. Its licenses carry potential milestone and royalty obligations, including up to $275 million in commercial milestones under the Mabwell agreement, contingent on future events. The filing reports no material pending legal proceedings.
Ernst & Young LLP issued an unqualified opinion on the consolidated financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the filing did not include an auditor attestation on internal controls because of the company’s emerging-growth-company exemption.
Most important facts for investors to verify
- Whether AURORA results confirmed a clinically meaningful benefit, and how they compare with the interim, open-label BEACON findings.
- Whether DISC-0974’s early biomarker and hemoglobin findings translate into durable clinical benefit in larger patient groups.
- Actual cash burn, spending plans and runway as trials advance; the stated “well into 2026” runway is based on management assumptions.
- Future equity issuance and dilution, including subsequent ATM sales; the filing reports $15.3 million of gross ATM proceeds through March 21, 2024.
- Clinical supply, manufacturing readiness and the timing and scale of contingent license milestone payments.